Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is one of 902 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.
Earnings and Valuation
This table compares Eloxx Pharmaceuticals and its peers gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | $6.36 million | -$5.99 million | -10.39 |
| Eloxx Pharmaceuticals Competitors | $3.56 billion | $3.15 billion | 547.52 |
Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| Eloxx Pharmaceuticals Competitors | -2,319.23% | -223.52% | -16.98% |
Insider & Institutional Ownership
2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings for Eloxx Pharmaceuticals and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 0 | 2 | 2 | 3.00 |
| Eloxx Pharmaceuticals Competitors | 7617 | 13668 | 25504 | 1003 | 2.42 |
Eloxx Pharmaceuticals currently has a consensus target price of $38.33, suggesting a potential upside of 139.58%. As a group, “Pharmaceuticals” companies have a potential upside of 27.78%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than its peers.
Risk and Volatility
Eloxx Pharmaceuticals has a beta of -1862.26, meaning that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of -3.17, meaning that their average stock price is 417% less volatile than the S&P 500.
Summary
Eloxx Pharmaceuticals beats its peers on 7 of the 13 factors compared.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
